Signal Prioritisation in Pharmacovigilance

Introduction

Signal prioritisation is the process through which validated signals are evaluated to determine the level of attention, resources and urgency that should be assigned to further assessment activities.

Not all validated signals carry the same potential significance. Some signals may involve serious adverse reactions with possible public health implications and require immediate review. Others may involve observations that are clinically important but unlikely to require urgent action. Some signals may require continued monitoring while additional information becomes available.

Prioritisation provides a structured framework for allocating resources appropriately and ensuring that potentially important safety concerns receive timely attention.

The objective is not to determine whether a signal is causal. That question is addressed during signal assessment. Instead, prioritisation seeks to determine how urgently and extensively a signal should be investigated.

Signal Prioritisation Within the Signal Management Process

Signal prioritisation generally occurs after validation and before detailed assessment.

A simplified process can be represented as:

Signal Detection
        ↓
Signal Validation
        ↓
Signal Prioritisation
        ↓
Signal Assessment
        ↓
Recommendation
        ↓
Action or Closure

Although not always described as a separate stage, prioritisation occurs implicitly or explicitly within most signal management systems.

Without prioritisation, organisations may struggle to distinguish between observations requiring immediate attention and those suitable for routine evaluation.

Why Prioritisation Is Necessary

Modern pharmacovigilance systems generate substantial volumes of signal-related information.

Potential signals may arise from:

• Spontaneous reports
• Literature surveillance
• Clinical studies
• Epidemiological research
• Regulatory communications
• EudraVigilance analyses

Even after validation, the number of signals requiring assessment may exceed available resources.

Prioritisation therefore serves several purposes:

• Efficient allocation of resources
• Timely management of significant risks
• Consistent decision-making
• Improved governance
• Enhanced public health protection

The process helps organisations focus attention where it is likely to have the greatest impact.

Principles of Risk-Based Prioritisation

Most prioritisation systems utilise a risk-based approach.

The purpose is not to rank signals according to statistical strength alone.

Instead, prioritisation considers broader factors that may influence the potential significance of the observation.

These factors often include:

• Clinical severity
• Public health impact
• Strength of evidence
• Extent of exposure
• Regulatory implications
• Benefit-risk considerations

A relatively small number of reports may warrant high prioritisation if the potential consequences are sufficiently serious.

Clinical Severity

The seriousness of the event is often one of the most important prioritisation factors.

Signals involving:

• Fatal outcomes
• Life-threatening events
• Permanent disability
• Congenital anomalies
• Serious organ toxicity

may warrant accelerated assessment even when evidence remains limited.

Clinical severity frequently influences both prioritisation decisions and escalation pathways.

However, seriousness alone should not determine priority. Other factors should also be considered.

Public Health Impact

Public health impact refers to the potential consequences of a signal at the population level.

Factors that may influence public health impact include:

• Number of exposed patients
• Vulnerable populations
• Widespread product use
• Potential preventability
• Availability of alternatives

A moderately severe risk affecting millions of patients may warrant greater attention than a severe risk affecting a very small population.

Assessment of public health impact therefore requires consideration of both severity and exposure.

Strength of Evidence

Prioritisation should consider the quality and consistency of available evidence.

Relevant factors may include:

• Number of reports
• Quality of reports
• Consistency across sources
• Biological plausibility
• Supporting literature
• Epidemiological evidence

Signals supported by multiple independent evidence sources may receive higher priority than observations based upon limited or uncertain information.

However, strong evidence is not always necessary for high prioritisation if the potential consequences are sufficiently serious.

Novelty

Novelty may influence prioritisation decisions.

Questions commonly considered include:

• Is the event already recognised?
• Does the signal represent a new risk?
• Does the signal represent a new aspect of a known risk?
• Has the issue been assessed previously?

Completely new safety concerns may warrant greater attention than issues that have already been extensively characterised.

Novelty is particularly important when considering potential regulatory implications.

Benefit-Risk Implications

Prioritisation should consider whether a signal may influence the benefit-risk balance of the medicinal product.

Questions may include:

• Could the signal alter prescribing decisions?
• Could the signal affect approved indications?
• Could the signal require additional monitoring?
• Could the signal affect patient safety significantly?

Signals with potential benefit-risk implications often require visibility within broader pharmacovigilance governance structures.

Regulatory Significance

Certain signals may have greater regulatory significance than others.

Examples include signals that may:

• Trigger regulatory communications
• Require product information updates
• Lead to risk minimisation measures
• Generate requests for additional studies
• Influence ongoing regulatory procedures

Potential regulatory impact frequently contributes to prioritisation decisions.

Emerging Safety Issues

Potential emerging safety issues generally represent the highest level of prioritisation.

These situations may require:

• Accelerated assessment
• Senior management visibility
• QPPV awareness
• Regulatory communication

Because emerging safety issues may affect public health directly, governance systems should support rapid prioritisation and escalation.

Prioritisation Methodologies

Organisations utilise a variety of prioritisation approaches.

Some employ formal scoring systems.

Others rely primarily on structured medical review.

Common approaches include:

• Risk matrices
• Priority categories
• Scoring algorithms
• Expert review panels

The specific methodology is generally less important than consistency and scientific justification.

Inspectors typically focus on whether prioritisation decisions are understandable and reproducible.

Governance of Prioritisation

Signal prioritisation should operate within a defined governance framework.

Governance arrangements commonly define:

• Review responsibilities
• Escalation criteria
• Priority categories
• Decision-making authority
• Documentation requirements

Prioritisation decisions may be reviewed by:

• Signal review committees
• Safety management teams
• Product safety committees
• Benefit-risk governance groups

Formal governance helps ensure consistency across products and therapeutic areas.

Documentation Requirements

Prioritisation decisions should be documented appropriately.

Records may include:

• Signal description
• Evidence reviewed
• Priority classification
• Supporting rationale
• Escalation decisions
• Assigned actions

Documentation should enable reconstruction of the prioritisation process.

Inspectors frequently examine whether priority assignments can be justified using available records.

Role of the QPPV

The QPPV is not typically responsible for assigning priority classifications to individual signals.

However, governance arrangements should ensure that highly prioritised signals and potential emerging safety issues become visible to the QPPV.

The QPPV should understand:

• How prioritisation decisions are made
• Which signals require escalation
• How urgent concerns are managed
• How prioritisation influences assessment activities

Inspectors commonly explore these topics during discussions of signal management oversight.

Prioritisation During Inspections

Signal prioritisation may be reviewed explicitly or indirectly during inspections.

Inspectors may examine:

• Prioritisation procedures
• Escalation records
• Governance documentation
• Assessment timelines
• Resource allocation decisions

Inspection findings frequently arise when organisations cannot explain why certain signals received limited attention or why escalation decisions were made.

The rationale supporting prioritisation decisions should therefore be clear and documented.

Common Prioritisation Failures

Several weaknesses occur repeatedly across organisations.

Over-Reliance on Statistical Strength

Signals are prioritised solely according to disproportionality metrics.

Failure to Consider Public Health Impact

Exposure and population-level consequences are ignored.

Inconsistent Decision-Making

Similar signals receive different prioritisation outcomes.

Poor Documentation

Priority assignments cannot be justified retrospectively.

Weak Escalation Processes

Highly significant signals are not escalated appropriately.

Limited Governance

Prioritisation decisions occur without appropriate oversight.

These weaknesses may affect both compliance and safety oversight.

Characteristics of Effective Prioritisation Systems

Effective prioritisation systems generally demonstrate:

• Risk-based decision-making
• Consistent application
• Defined governance structures
• Appropriate escalation pathways
• Clear documentation
• Integration with benefit-risk evaluation

The objective is not to predict regulatory outcomes but to ensure that resources are directed toward the most significant safety concerns.

Key Takeaways

Signal prioritisation is the process through which validated signals are assigned an appropriate level of urgency and attention.

Prioritisation considers factors such as clinical severity, public health impact, strength of evidence, novelty and potential benefit-risk implications.

The process supports efficient resource allocation and timely management of significant safety concerns.

Governance, documentation and escalation pathways are important components of effective prioritisation systems.

QPPVs should maintain visibility of highly prioritised signals and potential emerging safety issues through established governance mechanisms.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module IX – Signal Management.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems.
4. Commission Implementing Regulation (EU) No 520/2012.
5. CIOMS VIII Practical Aspects of Signal Detection in Pharmacovigilance.
6. ICH E2E Pharmacovigilance Planning.
7. ICH E2C(R2) Periodic Benefit-Risk Evaluation Report.